导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.76% | 1164/4773 |
| 近一周 | -0.66% | 1697/5467 |
| 近一月 | -5.81% | 2620/5421 |
| 近一季 | -9.07% | 2900/5238 |
| 近半年 | -1.39% | 1927/4931 |
| 近一年 | 10.20% | 1025/4400 |
| 近两年 | 84.57% | 769/2954 |
| 近三年 | 50.16% | 545/2253 |
| 成立以来 | 18.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.28% 980/4961 |
18.88% 1339/5312 |
- - |
- - |
| 2025 | 33.03% 1138/4813 |
2.47% 1362/3635 |
2.17% 1798/4076 |
24.76% 1438/4524 |
1.85% 1187/4813 |
| 2024 | 11.35% 1330/3463 |
-2.02% 1307/2808 |
-4.95% 1600/3014 |
16.52% 1431/3129 |
2.61% 920/3463 |
| 2023 | -4.02% 660/2656 |
7.83% 520/2280 |
-3.53% 818/2385 |
-3.89% 1010/2515 |
-4.00% 839/2655 |
| 2022 | -16.38% 474/2207 |
-13.02% 685/1919 |
3.44% 1152/2016 |
-9.80% 311/2113 |
3.04% 778/2208 |
| 2021 | 21.35% 162/1822 |
-0.84% 399/1255 |
10.89% 424/1330 |
5.91% 250/1466 |
4.21% 356/1822 |
| 2020 | 29.15% 545/1250 |
-3.25% 294/1028 |
17.25% 381/1067 |
9.44% 649/1164 |
4.02% 877/1184 |
| 2019 | 28.86% 514/1092 |
30.53% 243/739 |
-9.57% 668/788 |
2.17% 318/850 |
6.85% 535/918 |
| 2018 | -30.26% 466/834 |
- - |
-12.94% 419/631 |
-6.93% 418/660 |
-12.18% 421/682 |
| 2017 | 3.12% 432/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.22% 352/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 华泰柏瑞中证500ETF联接A VS. 长安沪深300非周期A(740101) |